Rezdiffra (Resmetirom) Cost in Georgia 2026

What Does Rezdiffra (Resmetirom) Actually Cost in Georgia?

Rezdiffra carries a wholesale acquisition cost of roughly $3,500 per month in 2026, and Georgia retail pharmacies price it at or near that figure for cash-pay patients. That works out to approximately $42,000 per year before any insurance, rebate, or assistance program reduces the number.

Madrigal Pharmaceuticals set this price at launch following the March 2024 FDA approval, making resmetirom the first approved pharmacologic treatment for metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis [1, 2]. No generic exists. No authorized generic has been announced for 2025 or 2026.

Why the List Price Is So High

Specialty hepatology drugs routinely carry five-figure annual price tags. Resmetirom targets thyroid hormone receptor beta (THR-beta) selectively in the liver, a mechanism that required roughly a decade of clinical development [3]. Madrigal's MAESTRO-NASH trial enrolled 966 patients across 107 sites and ran for 52 weeks, representing a large Phase 3 investment [4].

Cost alone does not determine what a Georgia patient actually pays. The sections below break down each real-world pathway.

Cash-Pay Reality for Georgia Patients

Without insurance and without assistance programs, a Georgia patient fills Rezdiffra at around $3,500 per month. GoodRx and similar discount platforms do not meaningfully cut the price on branded specialty drugs under patent, so coupons posted online for Rezdiffra should be verified against the Madrigal Assist program directly.

Most Georgia patients do not pay list price. The Madrigal Assist program (covered in detail below) brings that figure to $0 per month for qualifying commercially insured individuals.

Georgia Medicaid and Rezdiffra Coverage

Georgia Medicaid does not cover Rezdiffra for the MASH indication as of 2026. The state's Preferred Drug List restricts coverage to patients whose resmetirom use would qualify under a type 2 diabetes (T2D) pathway, which does not apply to the FDA-approved MASH label [5].

What This Means for Georgia Medicaid Enrollees

Patients enrolled in Georgia Medicaid (including the CMOs: Amerigroup Georgia, Peach State Health Management, WellCare of Georgia, and Caresource Georgia) face a coverage gap. Prescribers may attempt a prior authorization exception citing the MAESTRO-NASH efficacy data, but denials remain common given the state formulary position [6].

A Medicaid enrollee whose liver disease has progressed to cirrhosis (F4 fibrosis) falls outside the approved indication entirely. Rezdiffra's FDA label restricts use to F2 and F3 fibrosis [1]. Cirrhotic patients should discuss alternative management with a hepatologist rather than pursuing Rezdiffra.

Medicare Part D Coverage in Georgia

Most Medicare Part D plans in Georgia place Rezdiffra on Tier 5 (specialty tier) with 25-33% coinsurance after the deductible. Following the Inflation Reduction Act changes, Medicare Part D out-of-pocket costs are capped at $2,000 per year starting in 2025 [7]. A Georgia patient on a Part D plan with Rezdiffra covered may reach the catastrophic cap by month two or three of therapy.

Patients should call their Part D plan's specialty pharmacy before filling to confirm the current tier and confirm that MASH with F2/F3 fibrosis meets the plan's coverage criteria.

Commercial Insurance Prior Authorization in Georgia

Every major commercial insurer operating in Georgia requires prior authorization (PA) for Rezdiffra. PA criteria vary by plan but generally require all of the following [8]:

• A confirmed MASH diagnosis (not simply steatosis or NAFLD)
• Liver fibrosis staging of F2 or F3 by biopsy or validated non-invasive method (FibroScan, ELF test, or FIB-4 index)
• Documentation that the patient's BMI qualifies under the plan's metabolic criteria
• A prescribing gastroenterologist or hepatologist (some plans deny PA from internal medicine or family medicine alone)

Step Therapy and Reauthorization

Several Georgia Blues (Anthem BCBS Georgia), Cigna, and Aetna plans require step therapy through lifestyle intervention documentation before approving Rezdiffra. The FDA label itself notes that Rezdiffra is indicated as an adjunct to diet and exercise [1], so documentation of a structured weight-loss attempt (typically 3-6 months) strengthens the PA file.

Reauthorization is required every 12 months. The MAESTRO-NASH data showed that 26% of patients on resmetirom 100 mg achieved MASH resolution without worsening fibrosis at 52 weeks versus 10% placebo (P<0.001) [4], a statistic that is useful language in PA appeals.

Appealing a Denial

Georgia follows the Georgia Patient Protection Act, which gives patients the right to an expedited external review. If a plan denies Rezdiffra on formulary grounds and the prescriber documents clinical necessity (biopsy-proven F2/F3 MASH, failed lifestyle intervention), an external review through the Georgia Office of Insurance and Safety Fire Commissioner can overturn the denial [9].

The Madrigal Assist Savings Card in Georgia

Madrigal Pharmaceuticals operates the Madrigal Assist program for commercially insured U.S. Patients, including those in Georgia. Eligible patients pay $0 per month for Rezdiffra [10].

Eligibility Requirements

To qualify for the $0 copay through Madrigal Assist, a patient must:

1. Have commercial (private) insurance. Patients with Medicare, Medicaid, or any federal or state government-funded plan are excluded.
2. Have a valid Rezdiffra prescription from a licensed U.S. Prescriber.
3. Be a resident of a state where the program is offered (Georgia is included).
4. Meet income limits if applying for the patient assistance program (PAP) track, which covers uninsured patients separately.

Madrigal also operates a separate PAP for uninsured or underinsured patients who meet income criteria, potentially providing the drug at no cost. Enrollment requires documentation of income and insurance status. The program is managed through a specialty pharmacy hub and can be initiated by the prescribing office or the patient directly at 1-800-MADRIGAL (verify the current number at madrigalpharma.com).

How to Enroll

The prescriber's office typically submits the PA and the Madrigal Assist enrollment simultaneously through the hub. Georgia patients can expect a 3-7 business day turnaround for commercial insurance cases without complications. Medicaid and uninsured patients using the PAP track may face a 2-4 week review.

Is Compounded Resmetirom Legal in Georgia?

Yes. Compounded resmetirom is available in Georgia through licensed 503A compounding pharmacies, but the legal and clinical picture requires careful reading.

503A vs. 503B Compounding

A 503A pharmacy compounds for individual patients on a per-prescription basis. Georgia-licensed 503A compounding pharmacies may prepare resmetirom for a specific patient if a licensed prescriber writes the order. The pharmacy must source resmetirom as a bulk active pharmaceutical ingredient (API) from an FDA-registered supplier.

A 503B outsourcing facility compounds in large batches without individual prescriptions. Resmetirom is not currently on the FDA's 503B drug shortage list, which means 503B bulk compounding of resmetirom sits in a regulatory gray zone [11]. The FDA has warned compounders against producing copies of commercially available drugs that are not on the shortage list.

Clinical and Quality Considerations

Compounded resmetirom has not been evaluated in any published clinical trial. The pharmacokinetic profile of a compounded oral formulation may differ from Rezdiffra's proprietary tablet. The MAESTRO-NASH outcomes data apply specifically to Madrigal's formulation [4].

Patients considering compounded resmetirom should discuss bioavailability concerns with their prescriber and confirm that the compounding pharmacy is licensed by the Georgia State Board of Pharmacy and sources API from an FDA-registered facility [12].

Cost of Compounded Resmetirom in Georgia

Some Georgia 503A pharmacies quote compounded resmetirom at effectively $0 per month when dispensed through certain telehealth platforms that bundle the compounding cost into a membership fee. This pricing model is subject to change based on FDA regulatory actions and should be verified at the time of prescription. The "free" cost model typically involves a platform or telehealth visit fee that patients should factor into total spend.

Telehealth Prescribing of Rezdiffra in Georgia

Georgia law permits telehealth prescribing of Rezdiffra for patients who have an established patient-provider relationship, meet the diagnostic criteria, and have accessible liver fibrosis staging results [13]. A prescriber located outside Georgia may prescribe Rezdiffra to a Georgia patient via telehealth if the prescriber holds a valid Georgia medical license.

What a Telehealth Rezdiffra Visit Requires

A telehealth visit for resmetirom does not replace the diagnostic workup. Before prescribing, a clinician needs:

• Liver imaging or FibroScan results confirming F2 or F3 fibrosis
• Liver function tests (AST, ALT, bilirubin, INR) within 90 days
• A confirmed MASH diagnosis (histologic or by validated non-invasive algorithm)
• BMI and metabolic panel (fasting glucose, HbA1c, lipids)

If those records exist, a telehealth platform can review them, confirm eligibility, and submit the prescription and PA paperwork. The MAESTRO-NASH entry criteria required ALT elevation and biopsy-confirmed MASH with NAS score of 4 or higher [4], which gives prescribers a validated benchmark for patient selection.

Georgia Telehealth Platforms Offering Resmetirom

HealthRX connects Georgia patients to board-certified prescribers who can evaluate existing liver disease records, submit PA documentation, and, where clinically appropriate, support access to compounded resmetirom through licensed 503A pharmacies. An initial consultation requires uploading prior imaging, labs, and a brief intake questionnaire.

Clinical Evidence: Why Rezdiffra Costs What It Costs

Understanding the pricing context requires knowing what MAESTRO-NASH actually showed. Rezdiffra is the only FDA-approved drug for MASH with liver fibrosis; that regulatory exclusivity supports the price [1].

MAESTRO-NASH Trial Results

MAESTRO-NASH was a randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 966 adults with biopsy-confirmed MASH and F1b-F3 fibrosis [4]. Published in the New England Journal of Medicine in 2024, the 52-week results showed:

• 26% of patients on resmetirom 100 mg achieved the primary endpoint of MASH resolution (NAS reduction of 2+ points with no worsening of fibrosis) versus 10% placebo (P<0.001) [4]
• 24% of patients on resmetirom 100 mg achieved fibrosis improvement of one stage with no worsening of MASH versus 14% placebo (P<0.001) [4]
• LDL cholesterol fell by 13.6% from baseline in the 100 mg group versus a 0.1% decrease in placebo [4]

The Endocrine Society's 2023 clinical practice guideline on metabolic liver disease states: "Pharmacologic therapy for NASH should target both the inflammatory and fibrotic components of disease, as fibrosis stage is the strongest predictor of liver-related mortality" [15]. Resmetirom's dual effect on MASH resolution and fibrosis regression in MAESTRO-NASH positions it directly within that therapeutic rationale.

Safety Data Relevant to Prior Authorization Letters

Common adverse events in MAESTRO-NASH included nausea (26% resmetirom 100 mg vs. 11% placebo) and diarrhea (28% vs. 17%) [4]. Gallstone-related events occurred in 5.2% of the 100 mg group [4]. These are relevant because insurers sometimes cite safety concerns in denials; the published event rates can be used in PA appeals to contextualize risk against fibrosis-related outcomes [4].

Comparing Total Cost Pathways for Georgia Patients

The table below summarizes realistic total monthly out-of-pocket costs across the main access pathways available to Georgia patients in 2026.

| Pathway | Estimated Monthly OOP | Eligibility Condition | |---|---|---| | Commercial insurance + Madrigal Assist | $0 | Commercial insurance, valid PA | | Medicare Part D (post-IRA cap) | ~$167/month avg. (toward $2,000 annual cap) | Medicare enrollment, plan covers Rezdiffra | | Georgia Medicaid | Not covered (MASH indication) | N/A | | Uninsured + Madrigal PAP | $0 (income-qualified) | Income documentation required | | Cash pay, no assistance | ~$3,500/month | No restrictions | | Compounded resmetirom (503A, GA) | Variable ($0 to ~$300/month) | Prescriber order, licensed 503A pharmacy |

Georgia patients with commercial insurance who complete the PA process and enroll in Madrigal Assist face no monthly drug cost. The time investment is in the PA paperwork and diagnostic documentation, not the pharmacy bill.

How to Get Started: A Step-by-Step Pathway for Georgia Patients

Step 1: Confirm Your Fibrosis Stage

You need F2 or F3 fibrosis documented by liver biopsy, FibroScan (liver stiffness 8.2-14.0 kPa corresponds roughly to F2-F3), or the ELF panel. A FIB-4 index above 2.67 in a patient with metabolic risk factors may support a PA but is generally weaker than imaging [16].

Step 2: Obtain the Prescription

A Georgia-licensed gastroenterologist, hepatologist, or (via telehealth) a qualifying internal medicine physician can prescribe Rezdiffra. Dosing is 80 mg once daily for patients weighing <100 kg and 100 mg once daily for patients weighing 100 kg or more [1].

Step 3: Submit Prior Authorization

Your prescriber's office submits the PA to your insurance plan. Attach biopsy or FibroScan results, recent liver function tests, and documentation of lifestyle intervention attempts. Reference the MAESTRO-NASH 52-week data [4] in the clinical necessity statement.

Step 4: Enroll in Madrigal Assist

Simultaneously with the PA submission, ask the prescriber's office to enroll you in the Madrigal Assist hub. For commercially insured patients, this is the single most effective cost-reduction step available in Georgia.

Step 5: Fill at a Specialty Pharmacy

Rezdiffra is dispensed through specialty pharmacies, not standard retail. CVS Specialty, Walgreens Specialty, and Accredo serve Georgia patients. Confirm your plan's preferred specialty pharmacy before the prescription is routed.

Starting at 80 mg and titrating to 100 mg after 12 weeks (if tolerated and clinically indicated) follows the prescribing information and aligns with how MAESTRO-NASH patients were managed [4].